Chargement en cours...
Unusual Fatal Outcome Following Administration of a Combination of anti-PD1 and anti-CTLA4 in Metastatic Renal Cell Carcinoma: Liver Toxicity Case Report and a Literature Review
Hepatic dysfunction, in the absence of liver metastases, occurs in 10–15% of renal cell carcinoma (RCC) patients, while immune hepatitis due to anti-CTLA4 and anti-PD1 administration affects about 3–9% and 0.7–1.8% of treated patients, respectively. Liver toxicity following combination therapy (anti...
Enregistré dans:
| Publié dans: | Eur J Case Rep Intern Med |
|---|---|
| Auteurs principaux: | , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
SMC Media Srl
2021
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8276930/ https://ncbi.nlm.nih.gov/pubmed/34268267 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.12890/2021_002639 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|